Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 5, 2008

View Archived Issues

Escitalopram effective in treating multisomatoform disorder

NK-012 evaluated in phase I study in advanced cancer patients

Ki-20227 shows rheumatoid arthritis treatment potential in vivo

Recent patents describe new treatments for cardiovascular disorders

New therapeutic agents for genitourinary disorders reported in recent Roche patent

Florida International University patent discloses novel free radical scavengers

Otsuka and OncoTherapy Science enter license agreement for pancreatic cancer vaccine

Exercise-induced NMDA receptor activity prevents mature motor unit death in SMA

Bone Medical reports positive data from second clinical trial of CaPTHymone for osteoporosis

Epix reaches agreement with FDA for resubmission of Vasovist NDA

Solvay submits complete response to FDA approvable letter for Luvox CR

Eisai temporarily withdraws Japanese application for Pariet to conduct additional study

European Commission approves Novartis' Galvus as oral treatment for type 2 diabetes

Auris Medical completes patient enrollment in phase I/II trial with AM-101

Glenmark to get back global rights to melogliptin from Merck Serono

Pipex to meet with FDA following non acceptance of Coprexa NDA

Asmanex Twisthaler approved for asthma maintenance treatment in children

FDA grants orphan drug designation to VQD-002 in multiple myeloma

EU Commission grants broad approval of Xeloda in metastatic colorectal cancer

FDA approves Endeavor zotarolimus-eluting stent for clogged arteries

BioLineRx reports positive results from phase IIa BL-1020 trial in schizophrenia

Genzyme and Isis granted Hart-Scott-Rodino clearance for collaboration agreeement

First patient dosed in phase II trial of AGI-004 in chemotherapy-induced diarrhea

MedImmune submits BLA for motavizumab in the U.S.

EMEA grants positive opinion for GSK's Hycamtin in relapsed SCLC

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...